Who are Levothyroxine sodium new formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Evrenzo, Unithroid, Choloxin, Triostat, Euthyrox (levothyroxine), L-T4+T3 (thyroid tablet).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levothyroxine-sodium-new-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Levothyroxine sodium new formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levothyroxine sodium new formulation (Levothyroxine sodium new formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement. Area: Endocrinology.

phase 2 Thyroid hormone replacement Thyroid hormone receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Levothyroxine sodium new formulation (Levothyroxine sodium new formulation) — Takeda. Levothyroxine sodium acts on the thyroid hormone receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levothyroxine sodium new formulation TARGET	Levothyroxine sodium new formulation	Takeda	phase 2	Thyroid hormone replacement	Thyroid hormone receptor
Evrenzo	ROXADUSTAT	Astellas Pharma Europe B.V.	marketed		Thyroid hormone receptor beta	2021-01-01
Unithroid	LEVOTHYROXINE SODIUM	Fresenius Kabi	marketed	l-Thyroxine	Thyroid hormone receptor beta	2000-01-01
Choloxin	DEXTROTHYROXINE	AbbVie	marketed	dextrothyroxine	Thyroid hormone receptor	1967-01-01
Triostat	LIOTHYRONINE	Pfizer	marketed	l-Triiodothyronine	Thyroid hormone receptor alpha	1956-01-01
Euthyrox (levothyroxine)	Euthyrox (levothyroxine)	University Medical Center Groningen	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)
L-T4+T3 (thyroid tablet)	L-T4+T3 (thyroid tablet)	Zhongshan Hospital Xiamen University	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha, TR-beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement class)

Pfizer Inc. · 2 drugs in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
M. Medici · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Meyer Children's Hospital IRCCS · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sanofi · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levothyroxine sodium new formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/levothyroxine-sodium-new-formulation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing